Reduction in Radiation Exposure in Cardiovascular CT Imaging

PROspective Multicenter Registry on Radia**T**ion Dose **E**stimates of Cardiac **CT** Ang**IO**graphy I**N** Daily Practice in 2017 (PROTECTION VI)

Jörg Hausleiter

T. Stocker, S. Deseive, J. Leipsic, M. Hadamitzky, M.Y. Chen, R. Rubinshtein, M. Heckner, J.J. Bax, X.-M. Fang, E. Grove, J. Lesser, P. Maurovich-Horvat, J. Otton, S. Shin, D. Andreini, H. Marques, B. Chow, C.H. Nomura, R. Tabbalat, A. Schmermund, J.-W. Kang, C. Naoum, M. Atkins, E. Martuscelli, S. Massberg for the PROTECTION VI investigators ESC Congress

Munich 2018

Declaration of interest

- Research contracts (Abbott Vascular)



Radiation Dose in 2007



Hausleiter et al; JAMA 2009

PROTECTION II – V series









Hausleiter et al, JACC Imag 2011; Hausleiter et al, JACC Imag 2012 Deseive et al, JCCT 2015; Deseive et al, JACC Imag 2015

Rationale

to investigate in a real-world setting in 2017:

- the radiation dose of cardiac CTA (primary endpoint),
- the utilization and efficacy of established dose saving strategies, and
- the independent predictors for radiation dose



Methods

- PROTECTION VI is an international, industry-independent, multi-vendor, prospective, observational study.
- > 435 clinicians from 62 different countries were invited to participate
- Study investigators prospectively identified one calendar month in 2017 for participation and enrolled all consecutive patients
- Cardiac CTAs were carried out according to local standard of clinical care
- Cardiac CTA study details and CT images were collected and analyzed in a central core laboratory
- Registered at clinicaltrials.gov (NCT02996903)



Results

- 61 international sites (42 university hospitals, 19 community hospitals) from 32 different countries
- 51 patients (IQR 27 91 patients) per site during the month of enrollment;
- 4502 patients undergoing diagnostic cardiac CTA

ESC Congress



Study Site Characteristics

	2007 Dose Survey (1965 patients)	2017 Dose Survey (4502 patients)	
Site experience, years	3 (1.5 – 5.5) 10.5 (7.0 – 13.0)		
Number of CTAs/month	26 (10-46)	51 (27 – 93)	
CT system			
16-slice CT, % (n)	4% (72)	0%	
64-slice CT, % (n)	96% (1893) 9% (387)		
≥128-slice CT, % (n)	NA	91% (4115)	
CT manufacturer			
GE <i>,</i> % (n)	24 (466)	26 (1168)	
Philips, % (n)	8 (159)	13 (574)	
Siemens, % (n)	59 (1155)	48 (2160)	
Toshiba, % (n)	9 (185)	13 (600)	
LSC Congress			

 \mathbf{v} id

Patient Characteristics

	2007 Dose Survey (1965 patients)	2017 Dose Survey (4502 patients)	
Age, years	NA 60 (51 – 69)		
Male gender, % (n)	NA	58 (2623)	
BMI, kg/sqm	26.2 (23.8 – 28.8)	26.8 (24.1 – 30.1)	
Indication: Coronary, % (n)	82 (1611)	89 (4006)	
ß-Blocker medication Taking daily, % (n) Admin. for CTA, % (n)	12 (233) 46 (904)	13 (603) 53 (2370)	
Stable sinus rhythm, % (n)	95 (1874)	90 (4055)	
Heart rate, beats/min	61 (55 – 75)	60 (55 - 67)	

Coronary CTA Scan Protocols

	2007 Dose Survey (1611 patients)	2017 Dose Survey (4006 patients)	P-value
Scan length, mm	131 (118 – 144)	137 (125 - 157)	< .001
Tube potential ≤100kV, % (n)	5 (82)	56 (2226)	< .001
Low-pitch helical scan protocol, % (n)	94 (1512)	11 (447)	< .001
with ECG-correlated tube current modulation, % (n)	95 (1440)	73 (325)	< .001
Axial scan protocol, % (n)	6 (99)	78 (3094)	< .001
High-pitch helical scan protocol, % (n)	0 (0)	11 (449)	NA
Iterative image reconstruction, % (n)	O (0)	83 (3306)	NA

Coronary CTA: Dose



Munich 2018

Coronary CTA: Dose Variability



Regional Dose Results



Coronary CTA: Independent Predictors



Conclusions

The current PROTECTION VI survey demonstrates that :

- the radiation exposure from cardiac CTA has been considerably reduced by 78% over the last 10 years.
- This was mainly accomplished by an increased use of (a) low tube potential scan protocols, (b) prospectively ECG-triggered axial and high-pitch scan protocols, and (c) iterative image reconstruction.
- Given the high diagnostic accuracy and the low radiation dose, coronary CTA should be considered as a first-line diagnostic test.
- The large 37-fold inter-site variability in median radiation dose underlines the need for further site-specific training and adaptation of contemporary cardiac scan protocols.

PROTECTION VI Investigators

- 1. P. Carrascosa and A. Deviggiano, Diagnóstico Maipú, Buenos Aires, Argentina
- 2. C. Naoum and J. Magnussen, Macquarie University Hospital, Sydney, Australia
- 3. J. Otton and A. Kaplan, Spectrum Radiology Liverpool, Sydney, Australia
- 4. G. Feuchtner and F. Plank, Medizinische Universität, Innsbruck, Austria
- 5. K. De Smet and N. Buls, Universitair Ziekenhuis, Brussel, Belgium
- 6. R.C. Cury and M.S. Bittencourt, Delb
- 7. C.H. Nomura and R.N. Dantas Junior,
- 8. J. Leipsic and P. Blanke, University of
- 9. C. Chartrand-Lefebvre and A. Chin, U
- 10. G. Small and B. Chow, University of C
- 11. C. Silva F, Clinica Alemana de Santiag
- 12. M. Godoy Z. and C. Silva F., Clinica Al
- 13. X.-M. Fang and W. Jie, Wuxi People's
- 14. A. Cadena, Clínica de la Costa, Barrar
- 15. T. Adla and V. Suchanek, Motol Unive
- 16. E.L. Grove and K.B. Pedersen, Aarhus
- 17. J. Lambrechtse and M. Husic, OUH-S
- 18. J. Knuuti and T. Maaniitty, Turku Uni
- 19. B. Bischoff and E. Arnoldi, Klinikum d
- 20. A. Schmermund and J. Eckert, CCB, F
- 21. M. Hadamitzky and T. Finck, Deutsch
- 22. M. Hell and M. Marwan, Universitäts
- 23. F. Bamberg and S. Mangold, Universi
- 24. T. Schlosser and J. Ludwig, Universitä
- 25. M. Mylona and S. Skiadopoulos, Olyr
- 26. P. Maurovich-Horvat and B. Szilveszt
- 27. U. Jadav and B.V. Pinto, MGM New E
- 28. R. Rubinshtein and E. Hussein, Lady
- 29. D. Andreini and G. Pontone, Centro
- 30. E. Martuscelli and M. Sperandio, Poli
- 31. K. Kitagawa and N. Nagasawa, Mie U

32. R. Tabbalat and R.A. Farhan, Khalidi

ESC Congress Munich 2018



European Society doi:10.1093/eurheartj/ehy546 of Cardiology

Reduction in radiation exposure in

- 🖁 cardiovascular computed tomography imaging
 - results from the Prospective Multicenter
 - Registry on RadiaTion Dose Estimates of Cardiac CT AnglOgraphy IN Daily Practice in 2017 (PROTECTION VI)

Thomas J. Stocker^{1,2}, Simon Deseive^{1,2}, Jonathon Leipsic³, Martin Hadamitzky⁴, Marcus Y. Chen⁵, Ronen Rubinshtein⁶, Mathias Heckner¹, Jeroen J. Bax⁷, Xiang-Ming Fang⁸, Erik Grove⁹, John Lesser¹⁰, Pál Maurovich-Horvat¹¹, James Otton¹², Sanghoon Shin¹³, Gianluca Pontone¹⁴, Hugo Marques¹⁵, Benjamin Chow¹⁶, Cesar H. Nomura¹⁷, Ramzi Tabbalat¹⁸, Axel Schmermund¹⁹, Joon-Won Kang²⁰, Christopher Naoum²¹, Melany Atkins²², Eugenio Martuscelli²³, Steffen Massberg^{1,2}, and Jörg Hausleiter^{1,2}*; for the PROTECTION VI investigators[†]

- 33. L.M. Sierra Galán and L.A. Delgado, American British Cowdray Medical Center Observatory Campus, Mexico City, Mexico
- 34. L.M. Sierra Galán and M.A. Reza Orozco, American British Cowdray Medical Center Santa Fe Campus, Mexico City, Mexico
- 35. F.C. Castellón and M.D. Zamudio, Instituto Ignacio Chavez, Mexico City, Mexico

FASTTRACK CLINICAL RESEARCH Imaging	n, Mexico th Norway, Tromsø, Norway I Rikshospitalet, Oslo, Norway an-Pablo, Surco, Peru I Unit), Hospital da Luz, Lisbon, Portugal
osure in	e and Rehabilitation, Moscow, Russia er, Burydah, Saudi Arabia al. Jeddah. Saudi Arabia
omography imaging:	South Korea
ve Multicenter	eoul, South Korea rea arcelona, Spain
e Estimates of	ll Center, Leiden, Netherlands v of Edinburgh, Edinburgh, United
IN Daily Practice in	ital, Bournemouth, United Kingdom Albany, United States Ineapolis, United States Iwns Mills, United States
on Leipsic ³ , Martin Hadamitzky ⁴ ,	cal Center, Maywood, United States cal. San Antonio. United States

ted States

Inited States nited States litary Medical Center, Bethesda, United

d Blood Institute, National Institutes of

Sorted by country

Tube Potential and Dose



CT Manufacturer and Dose

